By Joe Miles, Global Vice President, Life Sciences, SAP
While there are remarkable things happening in life sciences at the moment, perhaps the most dramatic is the erosion of operating margins.
Branded pharmaceuticals continue to lose patent protection on key products. As a result, close to half a trillion dollars of branded revenue have gone over to the generic markets in the last ten years. It’s a dose of reality that has the biggest companies reeling.
For them, strategic restructuring....